Daxdilimab targets and depletes plasmacytoid dendritic cells, whereas litifilimab targets BDCA2 receptors on plasmacytoid dendritic cells to downregulate them without causing depletion

552c7ae14Space

Health

Health news, debates, and claims covering public health, mental health, nutrition, medical care, and health policy.

1 debate·6,984 claims·43 news stories

0